Role of Panitumumab in the Management of Metastatic Colorectal Cancer

摘要: Abstract Panitumumab (formerly known as ABX-EGF) is the first fully human monoclonal antibody directed against epidermal growth factor receptor in clinical use. It has proven to be very well tolerated alone and combination with other cytotoxic chemotherapeutic agents. demonstrated efficacy monotherapy standard agents a wide variety of cancer types, including non–small-cell lung cancer, renal, colorectal (CRC). To date, no antihuman antibodies have been detected, unlike cetuximab, infusion reactions are infrequent, premedications required when administering panitumumab. The only significant toxicity rash similar that seen targeting receptor, such predominantly mild moderate. In metastatic CRC, panitumumab safe efficacious given commonly used this disease, irinotecan fluorouracil. Current studies under way looking at FOLFOX (fluorouracil/leucovorin/oxaliplatin) plus bevacizumab novel yet come into common practice. Recent progress development management CRC reviewed, associated discussed herein.